Introduction
In Europe, the causative agent of Lyme borreliosis (LB) is the tick-transmitted spirochete Borrelia burgdorferi (B. burgdorferi) sensu lato, consisting mainly of the three genospecies B. burgdorferi sensu stricto (s.s.), B. garinii and B. afzelii. The most common clinical manifestation of LB is the skin rash erythema migrans (EM), followed by other manifestations such as neuroborreliosis, arthritis, acrodermatitis, lymphocytoma and carditis (Berglund et al., 1995) . The clinical manifestations of LB are classified into three different stages (I, II and III) according to localization and duration of infection. EM is an early clinical manifestation of LB and therefore regarded as stage I, whereas other manifestations indicate disseminated LB and belong to the later stages (II and III). The diagnosis of EM is generally based on patient history and typical skin rash. Laboratory confirmation, e.g. demonstration of anti-borrelial antibodies, is not usually recommended in the acute phase of EM due to low serosensitivity (20-50%). In stages II and III of LB, serosensitivity varies from 70% to nearly 100% (Wilske, 2005) . Therefore, there is a greater potential for improvement in serosensitivity in cases of EM compared to stages II-III. Furthermore, when studying the early immune response in LB, serology in patients with EM is of particular interest. Clinically an improved serosensitivity in EM can be of use in cases of atypical rash where misdiagnosis may occur (Feder and Whitaker, 1995) .
Recently, a commercial ELISA using a synthetic 26-mer peptide antigen called C6 has been evaluated and introduced in the serodiagnosis of LB (Cinco and Murgia, 2006; Smismans et al., 2006; Nyman et al., 2006; Tjernberg et al., 2007; Sillanpää et al., 2007) . The C6 antigen is based on the sixth invariant region (IR 6 ) of the variable major protein-like sequence, expressed (VlsE) by B. garinii (Liang et al., 1999) . Although strong antibody response has been shown against the C6 peptide regardless of infecting strain of borrelia (Liang et al., 2000) , there is evidence of variation in the IR 6 amino acid sequences between B. afzelii, B. garinii and B. burgdorferi B31 (Goettner et al., 2004) . The purpose of this study was to investigate patients with EM from an endemic area of Sweden and to compare early antibody responses to the C6 peptide and three IR 6 peptides representing the three main borrelial genospecies. In addition, we wanted to study the antibody responses over time and in relation to previously reported LB in order to determine differences in antibody response dynamics between different VlsE based antigens.
Material and methods
Patients with LB in Kalmar County in Sweden were prospectively included in a clinical study in 2003 (Tjernberg et al., 2007) . Clinical data was recorded in a study protocol and serum samples were drawn at the first consultation (sample I), at 2-3 months (sample II) and 6 months (sample III), see Table 1 and Table 2 . (Sillanpää et al., 2007, Table 3 ). In order to facilitate for the reader, the naming of the three IR 6 peptides has been kept the same in this study. The commercial C6 peptide ELISA based on a B. garinii sequence (Liang et al., 1999) was performed and interpreted according to the manufacturer's instructions (Quick ELISA C6
Borrelia assay kit, Immunetics®, USA). The version of the Immunetics® C6 test available at the time of this investigation used a conjugated antigen as a secondary measure to detect antibodies specific for the C6 peptide (personal communication Immunetics®). Thus, it was not selective for immunoglobulin classes. It was not fully comparable to the kit available on the market at the time of submission, where conjugated goat-anti-human IgG/IgM was used in the detection step. The IR 6 peptide antibody assays were performed as previously described (Heikkilä et al., 2003; Sillanpää et al., 2007) . Sera from the 148 patients with EM and blood donor sera (n=200) were also analysed by an independent Western Blot kit (EcoLine, Virotech, Germany) in order to exclude seropositive samples when calculating cut-off levels for the different IR 6 peptides and an alternative comparable cut-off level for the C6 peptide.
Western Blot results were also used to confirm reactivity in the ELISA experiments. Although the manufacturer provided a cut-off level for the C6 test (C6 Imm; > 0.15), an in house cut-off level (C6 IH; ≥ 0.0689) was also calculated using the same method as for the IR 6 peptides in Statistical analyses were performed using Fisher's exact two-tailed test for proportions and non-parametric tests (Mann-Whitney's U-test) when comparing OD values, age and symptom duration between groups (Statistica 7.1). A p < 0.05 was considered statistically significant.
Receiver operating characteristic curve (ROC) analysis was performed using MedCalc® software version 9.4.2.0. The study was approved by the regional ethical board of Linköping University, Sweden.
Results

Clinical features
Of 148 EM patients, 46 (31%) reported a previous episode of LB (Table 1) . Patients with selfreported, previous LB were older than those without previous LB (median 61 versus 54 years, p=0.01). Regarding associated symptoms or duration of EM at presentation, no significant differences between the two groups were found. Among patients reporting previous LB, women were significantly older than men (median 62 versus 56 years, p=0.01). No woman below 44 years of age reported previous LB.
Antibodies to C6 and IR 6 peptides
The proportion of positive serum samples in the IR 6 or C6 peptide ELISAs ranged from 32%
to 58% at presentation, from 30% to 52% at 2-3 months, and from 20% to 36% at 6 months (Table 2 : P1, P2, P4, C6 IH and C6 Imm.). Of the 148 patients at presentation, 97 (66%) were positive for any IR 6 or C6 IH peptide, and 11 (7%) were positive for one or more IR 6 peptides but not to C6 IH at presentation. At presentation, 76 (51%) patients were positive in P1 or C6
Imm., and 95 (64%) were positive in P1 or C6 IH. A total of 51 (34%) were all negative, and 36 (24%) were all positive in tested ELISAs (calculated data, not shown in Table) . Thus, full concordance was achieved in 51 negative and 36 positive samples at presentation (59%). No significant differences were found between women and men in seropositivity to IR 6 peptides or C6 IH/Imm (data not shown).
The proportion of positive samples for the three IR 6 peptides did not change significantly from sample I to sample II (P1: p=0.3523, P2: p=1.0, P4: p=0.3368), but decreased significantly to sample III regarding P1 and P4 (P1: p=0.0070, P4: p=0.0093, Table 2 ). For the C6 peptide, however, the seropositivity rate tended to decrease from sample I to sample II with a further decrease to sample III, changes being significant for C6 IH between all samples (Sample I-II: p=0.0074; Sample II-III: p=0.0069) and between samples II and III for C6 Imm.
(Sample I-II: p=0.3873; Sample II-III: p=0.0436). Of the 148 patients, 76 (51%), 79 (53%), or 54 (36%) were positive for either C6 Imm or P1 or both at presentation, at 2-3 months, and at 6 months, respectively (calculated data, not shown in Table) .
In patients with previous LB compared to those without previous LB, the seropositivity rate at presentation was significantly higher for all IR 6 peptides (p<0.02, data not shown) but not for C6 IH or C6 Imm (p=0.36 or p=0.10, respectively, data not shown)
The coefficient of determination (R To compare analytical performance at different sensitivity and specificity levels, ROC analysis was performed using the OD values of the IR 6 peptides and the C6 peptide from the 148 EM patients at presentation and the 171 selected blood donors (Figure 1 ). Area under curve (AUC) was calculated for all tests and compared pairwise. AUC in between IR 6 peptides did not differ significantly, however AUC for all IR 6 peptides were significantly higher (p≤0.021) than for the C6 peptide.
Of the selected 171 blood donor samples, two (1.0 %) were positive for P1, two, (1.0 %) for P2. and three (1.5 %) for P4 ELISA. In 52 patients, C6 IH was negative for all three samples. In nine of these patients, antibody responses to one or more of the IR 6 peptides were found, most frequently antibodies to P1, 7/52 (13%), see Table 4 . Correspondingly, 46 patients were negative in all IR 6 peptide tests in all three samples. In 15 of these patients, a positive antibody response was detected using the C6 IH cut-off, but none were regarded positive by the higher C6 Imm. cut-off (data not shown). 
Western blot analysis of patients with EM
Western Blot results in the 148 EM patients at presentation and during follow-up are shown in Table 5 . Already at presentation, IgG antibodies to the VlsE protein were found in 42% of the cases, and IgM antibodies against outer surface protein C in 39%. 
Discussion
This study demonstrated that while the majority of patients with EM showed concordant serological responses to the C6 peptide and IR 6 peptides at presentation, 41% of the patients revealed variable responses between the peptides originating from the three genospecies of B.
burgdorferi sensu lato. Interestingly, in 7/148 (5%) of the EM patients a seroresponse to the IR 6 peptide originating from B. burgdorferi s.s. was detected at presentation, while a negative response was noted in the C6 test using the even more stringent in house cut-off level. In all of these cases a positive VlsE IgG band was detected by Western Blot. Taken together, these results suggest there may be cases of early Borrelia infection in Europe that the C6 test may not detect.
Generally, seropositivity for the different IR 6 peptides corresponded well to recent findings in Finnish patients with EM (Sillanpää et al., 2007) . However, seropositivity for the C6 peptide was 36% at presentation in this study compared to 55% and 65% in Finnish and Slovenian patients with EM at diagnosis and to 91% in early localised LB in Dutch patients (Sillanpää et al., 2007; Smismans et al., 2006) . The variation in the C6 seropositivity rates between different studies may be related to differences in the patient material or timing of sampling. In addition, the relative distribution of different Borrelia genospecies in different geographical locations may explain the somewhat discrepant serological responses. Such differences have previously been documented: In a Finnish study, the majority of culture or PCR verified EM patients were positive for B. garinii (Oksi et al., 2001 ) while a recent Swedish study from Blekinge County showed a predominance of B. afzelii in a comparable patient material (Bennet et al., 2006) .
Taking into account the heterogeneity of the IR 6 region of the immunodominant surface protein VlsE among the three borrelial genospecies (Göttner et al., 2004 , Sillanpää et al., 2007 (Sillanpää et al., 2007) .
The higher seropositivity rate at presentation against the C6 peptide compared to the delayed seroresponse to the various IR 6 peptides (IgG) in our investigation could possibly be explained by the fact that the commercial diagnostic kit used was not selective for antibody classes. However, due to insufficient specificity we chose not to include IgM ELISAs for the respective IR 6 peptides. Also, detection of IgM antibodies to the various IR 6 peptides did not improve detection of EM cases as compared to IgG antibodies (data not shown). As suggested earlier, there may also be other methodological differences affecting the results (Sillanpää et al., 2007 (Liang et al., 1999) . The main conclusion of the present study, that the C6 test may not cover all cases of erythema migrans, is in line with Sillanpää et al. (2007) . However, the results from the present study showed the best correlation between the C6 ELISA and the B. garinii IR 6 peptide in contrast to the results by Sillanpää et al. (2007) where C6 correlated better with the B. burgdorferi sensu stricto IR 6 peptide. Moreover, in this study we have shown a number of C6 negative sera to be reactive with the B. burgdorferi sensu stricto IR 6 peptide.
This is a new finding not observed in the study by Sillanpää et al. (2007) .
In a highly endemic area for LB like Kalmar County in Sweden with a reported incidence of 160/100.000 inhabitants and year (Berglund et al., 1995) , an increasing part of the population will have experienced one or more episodes of LB. Reinfection in our endemic area is common, and was reported by 31% of the patients in this study. Although LB and multiple episodes of LB are primarily related to a certain part of the population with behavioural habits generating a higher risk of tick bites, the population which previously had LB will expand and may cause further difficulties that must be taken into account when interpreting borrelia serology. A known problem of borrelia serology in our area is a high seroprevalence (8-14%) in the healthy adult population most probably generated by a previous exposure to Borrelia with a persisting detectable antibody response for many years not related to clinical symptoms or signs (Tjernberg et al. 2007) . In this sense, seropositivity rates for all IR 6 peptides were indeed significantly higher in patients with self-reported previous LB as compared to those who did not report previous LB. However, regarding the C6 peptide this difference was not statistically significant suggesting that the C6 ELISA could be more suitable as a screening test for LB in individuals with a previous episode of LB. Another interesting finding was older age in women reporting previous LB in this study than in corresponding men. These results are con-sistent with the data previously published on reinfections of LB and gender differences (Jarefors et al., 2006) . Clinically, no significant differences were detected regarding associated symptoms based on previous LB or not in this study. These findings are in line with data from a recent American study (Nadelman and Wormser, 2007) .
The ROC analysis showed a steep drop of specificity in the C6 peptide ELISA when reaching a sensitivity of around 65% which was not seen in the IR 6 peptide ELISAs. This is probably due to the analytical design of the C6 peptide ELISA. Apparently, the OD values of the C6 peptide ELISA in the blood donors group are very close to the OD values in the EM patients when reaching that sensitivity. This limits the possibilities to sensitize the C6 assay by in house modifications.
Although this study showed that in the majority of Swedish patients with EM the seroresponse to the tested IR 6 peptides and the C6 peptide are concordant at presentation, there are clinical cases of EM with negative C6 peptide results that may be detected mainly by seroresponse to a B. burgdorferi s.s. derived IR 6 peptide. Also, there were differences in the dynamics of the serological response to the C6 peptide as compared to the tested IR 6 peptides. These results may depend on differences in test formulations and differences in antigenic properties between the peptides. In Europe, differences in the local geographical distribution of borrelial genospecies may cause variation in serological response depending on the specific antigen used. Perhaps, an ELISA using a mixture of the C6 peptide and a B. burgdorferi s.s. derived IR 6 peptide could be of value in the serodiagnosis of LB in Europe. Further studies of combinations of antibody responses to IR 6 peptides and the C6 peptide in other LB manifestations with or without previous LB and control cases are needed to address this issue.
